Alizapride
![]() | |
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, IM, IV |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 3 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.056.082 |
Chemical and physical data | |
Formula | C16H21N5O2 |
Molar mass | 315.377 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.[1]
References
[edit]- ^ Ballatori E, Roila F (September 2003). "Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy". Health and Quality of Life Outcomes. 1: 46. doi:10.1186/1477-7525-1-46. PMC 212194. PMID 14521717.